CORT250117P50000
- 2.30
- -0.80-25.81%
Corcept Therapeutics Newsroom
Will Corcept Therapeutics Incorporated (CORT) Make You Rich In 2025?
Corcept Therapeutics Presents Phase 3 Long-Term Extension Study Of Relacorilant Demonstrated Durable Cardiometabolic Improvements In Patients With Hypercortisolism
Express News | Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients With Hypercortisolism
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating
Corcept Therapeutics (CORT) Receives a Buy From Truist Financial
Insider Sale: Director at $CORT (CORT) Sells 2,200 Shares
Corcept Announces Primary Endpoint Met In Treatment Phase Of CATALYST Trial In Patients With Hypercortisolism And Difficult-To-Control Diabetes
Express News | Corcept Therapeutics Inc - Korlym Safety Profile Consistent With Label, No New Side Effects
Express News | Corcept Announces Positive Results in Treatment Phase of Catalyst Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
Optimistic Outlook for Corcept Therapeutics Amid Promising Developments and Regulatory Advantages
Correction to Corcept Therapeutics Shares Fall Article
Corcept Therapeutics Fall 7% After ALS Drug Fails Trial
Express News | Corcept Therapeutics Inc - Dazucorilant Patients Experienced More Gastrointestinal Upset Than Placebo
Corcept Announces Results From Phase 2 Study Of Dazucorilant In Patients With Amyotrophic Lateral Sclerosis; DAZALS Did Not Meet Its Primary Endpoint, Which Was The Change From Baseline In The ALS Functional Rating Scale-Revised In Patients Who...
Express News | Corcept Therapeutics Inc - Long-Term Extension Study to Assess Overall Survival in March 2025
Express News | Corcept Therapeutics Inc - No Deaths in 300 Mg Arm, 5 Deaths in Placebo Group
Express News | Corcept Therapeutics Inc - Dazals Study Did Not Meet Primary Endpoint
Express News | Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)